Scrip | What Does 2023 Hold for Biopharma?

Jan 2023

Originally posted by Scrip on January 9, 2023.

Tony Crisman, Managing Director in Lincoln’s Healthcare Group, shares his predictions for biopharma mergers and acquisitions (M&A) trends in 2023.

View the original article.

Summary

  • Tony Crisman, Managing Director in Lincoln International’s Healthcare Group, reveals several anticipated 2023 biopharma mergers and acquisitions trends with Scrip.

  • Sign up to receive Lincoln's perspectives

Contributor

Meet Professionals with Complementary Expertise

Related Perspectives

2022 Global Results

In 2022, Lincoln International continued to design and deliver meaningful solutions and outcomes for clients around the world. Our shared ambition for results achieved through collaboration, thoughtfulness and tailored approaches… Read More

Lincoln International Announces Managing Director Promotions 2022

Lincoln International, a global investment banking advisory firm, is pleased to announce the promotion of six Directors to Managing Director (MD), effective January 1, 2023. “Each of these individuals contributes… Read More

What’s Old is New Again: Value-Based Care Delivery in the Home

In 1930, physicians visiting patients in their residences represented 40 percent of all encounters. 20 years later this figure had fallen dramatically to just one visit in 10. By the… Read More

In Vivo Pharma Intelligence | The Growth Path for Drug Discovery Partners

Originally published by In Vivo Pharma Intelligence on November 15, 2022 James West, Director in Lincoln’s Healthcare Group, explains the key trends and mergers and acquisitions (M&A) dynamics in the… Read More